End-to-End TCR CRO · Shaanxi INFINITY-Biotechnology Co., Ltd.

TCR Discovery · Screening
Optimization · Validation

End-to-End TCR CRO | Allogeneic-HLA TCR Priming Technology

INFINITY-TCR specializes in end-to-end T cell receptor (TCR) research services. Our proprietary Allogeneic-HLA TCR Priming platform achieves 25–40× higher efficiency than conventional methods, completing the full TCR development cycle in as few as 9 days, empowering next-generation cancer immunotherapy.

🔬 Get a Custom Proposal Explore Platforms →

25–40×

Efficiency Boost
vs. Conventional Methods

Fastest TCR
Development Cycle

Parallel Screening
Groups Simultaneously

Partners
University·Hospital·Research Institute

Core Technology

Allogeneic-HLA TCR Priming

Breaking through traditional TCR screening bottlenecks — our engineered APC system co-cultured with allogeneic PBMC achieves ultra-high efficiency TCR discovery, bridging the complete pathway from antigen target to functional TCR.

⚡

Ultra-High Screening Efficiency

25–40× improvement over conventional methods. 24 parallel screening groups simultaneously, each covering 5–15 pHLA epitopes for large-scale high-throughput TCR capture.

25–40× Efficiency Boost

🕐

Rapid Development Turnaround

Fully optimized integrated workflow completes the entire TCR discovery cycle in as little as 9 days — from epitope screening to functional validation, dramatically shortening development timelines.

Fastest 9-Day Completion

🔬

Engineered APC System

Proprietary T2/K562 engineered APC cells stably expressing target HLA and co-stimulatory molecules (B7, CD58), providing the optimal activation microenvironment for TCR Priming.

T2/K562 Engineered APC

🧬

Single-Cell Precise Pairing

Single-cell sorting combined with TCR VDJ sequencing to precisely obtain TCRα/β chain pairing information, ensuring accuracy and completeness of functional TCR discovery.

TCRα/β Precise Pairing

🎯

JK-TCR NFAT Reporter System

Proprietary Jurkat-CD8-NFAT-GFP reporter cell line enables high-throughput TCR functional screening, precisely quantifying activation signals and assessing TCR activity multi-dimensionally.

HT Functional Screening

💊

Multi-Vector Delivery System

Lentiviral (>60%), retroviral (>80%), and mRNA-LNP (in development) delivery systems with digital PCR for precise copy number quantification, covering all gene delivery requirements.

>80% Transduction Efficiency

Seven Technology Platforms

End-to-End TCR CRO Platforms

Covering the full TCR development lifecycle, our 7 specialized platforms work in synergy as a one-stop solution, driving innovation in TCR-T cell therapy.

PLATFORM 01

Allogeneic-HLA TCR Discovery

24 parallel groups, each screening 5–15 pHLA epitopes. 25–40× efficiency boost. Fastest 9-day completion. Scalable high-throughput TCR capture.

24-Group Parallel 25–40× Efficiency 9-Day Cycle

PLATFORM 02

TCR Sequence Optimization

Codon optimization, SS-TCR disulfide engineering, constant region enhancement, and Sc-TCR single-chain conversion — multi-strategy approach to improve TCR functionality and stability.

Codon Optimization SS-TCR Sc-TCR

PLATFORM 03

TCR Gene Delivery & Expression

Lentiviral (>60%), retroviral (>80%) multi-vector system, mRNA-LNP in development. Digital PCR for precise expression level quantification.

Lentiviral >60% Retroviral >80% mRNA-LNP

PLATFORM 04

Engineered APC Cell System

T2/K562 engineered APC cells stably expressing target HLA and co-stimulatory molecules (B7, CD58) for optimal TCR Priming activation microenvironment.

T2/K562 B7 Co-stimulatory CD58

PLATFORM 05

JK-TCR NFAT Reporter System

Jurkat-CD8-NFAT-GFP reporter cell line enables high-throughput TCR functional screening, precise activation signal quantification, and multi-dimensional TCR activity assessment.

NFAT-GFP High-Throughput Screening Functional Quantification

PLATFORM 06

Epitope Screening & Validation

Mass spectrometry (MS), NetMHCpan prediction, QuickSwitch peptide exchange (>85% efficiency), and intracellular cytokine staining (ICS) — multi-technology combined validation.

Mass Spectrometry MS NetMHCpan ICS

PLATFORM 07

s-pHLA Tetramer System

Proprietary s-pHLA Tetramer/multimer with flow cytometry detection. Minimum detectable concentration 100pM, peak positivity rate 82.7%.

Proprietary 100pM Detection Limit 82.7% Positivity

Six-Step Standardized Process

Complete TCR Development Workflow

From antigen target to functional validation, our six-step standardized process covers the complete TCR development chain with QC checkpoints at each stage.

Epitope Screening & Affinity Validation

Bioinformatics prediction combined with QuickSwitch MFI quantitative validation. Validated targets: KRAS (HLA-A*02:01/03:01/11:01), WT1, NPM1.

📌 Deliverable: Epitope-HLA affinity data report

pHLA Tetramer Synthesis & T Cell Enrichment

Proprietary s-pHLA Tetramer/multimer synthesis; flow cytometry enrichment of antigen-specific T cells with positivity rate up to 82.7%.

📌 Deliverable: Tetramer detection report + enrichment results

Allogeneic-HLA TCR Priming

Engineered T2/K562 APC co-cultured with allogeneic PBMC. 24 parallel groups, 25–40× efficiency improvement. TCR capture completed in as little as 9 days.

📌 Deliverable: TCR-positive cells + capture efficiency report

Single-Cell Sorting + TCR VDJ Sequencing

Precision single-cell sorting followed by high-throughput TCR VDJ sequencing to obtain complete TCRα/β chain pairing information with assured accuracy.

📌 Deliverable: TCRα/β paired sequences + clonal analysis

TCR Optimization & Gene Delivery

Codon optimization and SS-TCR engineering, combined with lentiviral (>60%) or retroviral (>80%) delivery. Digital PCR for precise copy number quantification.

📌 Deliverable: Optimized TCR sequence + expression vector + transduction efficiency report

Comprehensive Functional Validation

ICS (IFNγ/IL-2), JK-TCR NFAT reporter assay, TCR-T killing assay, peptide titration (100pM–10μM), and off-target safety panel.

📌 Deliverable: Complete functional validation report + safety data

Experimental Data

Real Experimental Results

The following showcases real experimental data from the INFINITY-TCR platform, including 24-group parallel pHLA TCR screening flow cytometry data and 9-day/45-day TCR development workflow validation data.

24-Group Parallel pHLA TCR Screening — Flow Cytometry Data

Allogeneic-HLA TCR Priming platform, 24 groups simultaneously, peak Tetramer positivity rate 82.7%

9-day/45-day TCR development workflow and IFNgamma ICS validation data

TCR Development Workflow Validation (9-day / 45-day)

IFNγ⁺CD8⁺ double-positive 16.3% (control 1.24%), IFNγ ICS functional validation results

82.7%

Peak Tetramer Positivity

16.3%

IFNγ⁺CD8⁺ Double Positive
(control group 1.24%)

>85%

Peptide Exchange Efficiency

100pM

Min. Detectable Conc.

Cases

Active Collaboration Projects

In-depth collaborations with leading medical institutions and research institutes, covering multi-cancer TCR development projects.

#	Target	Indication	Status	Partners
1	WT1-126	Blood tumors, Ovarian cancer	In vitro done · Patent published	Shanghai Ruijin Hospital
2	EBV	Nasopharyngeal, Gastric cancer	CTL screening in progress	Shanghai Ruijin Hospital
3	NPM1	Blood tumors, Ovarian cancer	In vitro killing validated	Xi'an Jiaotong University
4	KRAS	Lung cancer, Pancreatic cancer	In vitro ongoing · Patent filed	Xi'an Jiaotong University
5	KRAS	Lung cancer, Pancreatic cancer	In vitro ongoing · Patent filed	Army Medical University
6	Transplant-reactive	Graft-versus-host disease	Testing	Zhejiang Univ. 2nd Affiliated Hospital
7	Undisclosed	Breast cancer	TCR functional validation	XJTU 2nd Affiliated Hospital
8	Multiple Targets	Cervical, Pancreatic cancer	In vitro killing validated	CAS SINH / Army Medical Univ. / China Pharmaceutical Univ.

About

Shaanxi INFINITY-Biotechnology Co., Ltd.

INFINITY-TCR (Shaanxi INFINITY-Biotechnology Co., Ltd.), founded in 2021, specializes in T cell receptor (TCR) discovery, screening, optimization, and validation, providing end-to-end CRO services for TCR-T cell therapy development.

Our proprietary Allogeneic-HLA TCR Priming core technology platform, through engineered APC cell lines co-cultured with allogeneic PBMC, achieves 25–40× higher TCR screening efficiency than conventional methods, completing the full TCR discovery workflow in as little as 9 days — effectively addressing the industry pain points of long development cycles and low efficiency.

Headquartered in Western Cloud Valley, Fengxi New Town, Xixian New Area, Shaanxi, the company has established strategic partnerships with leading 985/211 universities, top-tier hospitals, and internationally renowned research institutions. Services span oncology immunotherapy, infectious diseases, and autoimmune conditions.

Founded2021

HeadquartersXixian New Area, Shaanxi, China

TechnologyAllogeneic-HLA TCR Priming

Partners8+ University·Hospital·Research Institute

Key Technical Metrics

Retroviral Transduction

>80%

Lentiviral Transduction

>60%

Peptide Exchange Efficiency

>85%

Peak Tetramer Positivity

82.7%

IFNγ⁺CD8⁺ Double-Positive (vs control 1.24%)

16.3%

Contact

Start a Collaboration

Fill in your inquiry and our expert team will get back to you within 24 hours with a personalized TCR development proposal.

Contact Information

📧

Business Email bd@infinity-tcr.com

📞

Phone +86 186 9185 8243

🌐

Website www.infinity-tcr.com

📍

Address Phase II, Western Cloud Valley 7A, Fengxi, Xixian New Area, Shaanxi, China

WeChat: TCRshows Scan to follow for the latest updates

📋 Send an Inquiry

Name *

Institution *

Email *

Service Type

Project Description

TCR Discovery · Screening
Optimization · Validation